QUINACRINE

US Previously Marketed

Details

Stereochemistry	RACEMIC
Molecular Formula	C23H30ClN3O
Molecular Weight	399.957
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC3=CC=C(OC)C=C13

InChI

InChIKey=GPKJTRJOBQGKQK-UHFFFAOYSA-N

InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)

HIDE SMILES / InChI

Molecular Formula	C23H30ClN3O
Molecular Weight	399.957
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm486146.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mmx/mepacrine.html

Quinacrine was initially developed as an anti-malarial drug marketed under the name Atabrine. Also it was approved for the teratment of ascites, however it was wothdrawn for both indication in 1995 and 2003, respectively. The drug is also used for the treatment of giardiasis, lupus, rheumatoid arthritis, refractory pulmonary effusion and pneumothorax, induce female sterilization etc. Proposed mechanisms of action include DNA intercalation interference with RNA transcription and translation, inhibition of succinate oxidation interference with electron transport, inhibition of cholinesterase, and inhibitor of phospholipase.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Malaria 96 Sources: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm486146.pdf	Preventing	Withdrawn	Atabrine Approved Use For the treatment of ascites due to various cancers, malaria, cestodiasis and giardiasis.
Ascites due to various cancers 3 Sources: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm486146.pdf	Primary	Withdrawn	Atabrine Approved Use For the treatment of ascites due to various cancers, malaria, cestodiasis and giardiasis. Launch Date 1964
Giardiasis 13 Sources: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm486146.pdf	Curative	Withdrawn	Atabrine Approved Use For the treatment of ascites due to various cancers, malaria, cestodiasis and giardiasis.
Cestodiasis 3 Sources: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm486146.pdf	Curative	Withdrawn	Atabrine Approved Use For the treatment of ascites due to various cancers, malaria, cestodiasis and giardiasis.

Doses

Dose	Population	Adverse events
300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) Health Status: unhealthy Age Group: 60.5 years (range: 40–75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	Other AEs: Distress gastrointestinal, Blood alkaline phosphatase abnormal... Other AEs: Distress gastrointestinal (serious, 1 patient) Blood alkaline phosphatase abnormal (3 patients) ALT increased (3 patients) Aspartate aminotransferase abnormal (3 patients) GGTP abnormal (3 patients) Seizure (serious, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/24122181

AEs

AE	Significance	Dose	Population
ALT increased	3 patients	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) Health Status: unhealthy Age Group: 60.5 years (range: 40–75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/24122181
Aspartate aminotransferase abnormal	3 patients	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) Health Status: unhealthy Age Group: 60.5 years (range: 40–75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/24122181
Blood alkaline phosphatase abnormal	3 patients	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) Health Status: unhealthy Age Group: 60.5 years (range: 40–75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/24122181
GGTP abnormal	3 patients	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) Health Status: unhealthy Age Group: 60.5 years (range: 40–75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/24122181
Distress gastrointestinal	serious, 1 patient	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) Health Status: unhealthy Age Group: 60.5 years (range: 40–75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/24122181
Seizure	serious, 1 patient	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) Health Status: unhealthy Age Group: 60.5 years (range: 40–75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/24122181

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C19 2057	CYP3A5 446 CYP3A7 109 CYP1A1 389 CYP1A2 1197 CYP4A11 137 CYP2B6 776 CYP2C8 810 CYP2C19 1119 P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://aac.asm.org/content/63/9/e01142-19	yes [IC50 0.013 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://aac.asm.org/content/63/9/e01142-19	yes [IC50 3.96 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://aac.asm.org/content/63/9/e01142-19	yes [IC50 6.66 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://aac.asm.org/content/63/9/e01142-19	yes [IC50 8.66 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://aac.asm.org/content/63/9/e01142-19	yes [IC50 >50 uM]

Drug as victim

Target	Modality	Activity
CYP1A1 389	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
CYP2B6 776	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
CYP2C8 810	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
CYP3A7 109	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
CYP4A11 137	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
P-gp 2052	substrate 4014 Sources: https://aac.asm.org/content/63/9/e01142-19	unlikely
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	yes
CYP3A5 446	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	yes

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-049679	http://www.3bsc.com/index/pro_info.php?id=87256
AA Blocks	AA0035HC	https://www.aablocks.com/goods/Goods/detail?id=AA0035HC
Aaron Chemicals	AR003694	http://www.aaronchem.com/69-05-6
AbMole Bioscience	M3183	http://www.abmole.com/products/quinacrine-dihydrochloride.html
AbMole Bioscience	M5132	http://www.abmole.com/products/quinacrine-dihydrochloride-dihydrate.html
Achemtek	0102-012688	http://www.achemtek.com/83-89-6
Achemtek	0102-012689	http://www.achemtek.com/69-05-6
AHH Chemical co.,ltd	MT-22110	http://www.ahhchemical.com/product/MT-22110.html
Ambeed	A266175	https://www.ambeed.com/products/69-05-6.html
Ambinter	Amb2198111	http://www.ambinter.com/reference/2198111
Ambinter	Amb2444874	http://www.ambinter.com/reference/2444874
Ark Pharm	AK01050742	http://www.arkpharminc.com/products/69-05-6.html
Aronis	ARONIS014439	http://www.aronis.ru/store/index.php?main_page=product_info&cPath=1&products_id=15606
Aurora Fine Chemicals LLC	A13.140.424	http://online.aurorafinechemicals.com/info?ID=A13.140.424
Aurora Fine Chemicals LLC	A17.866.451	http://online.aurorafinechemicals.com/info?ID=A17.866.451
Aurora Fine Chemicals LLC	A17.943.708	http://online.aurorafinechemicals.com/info?ID=A17.943.708
Aurora Fine Chemicals LLC	K01.172.209	http://online.aurorafinechemicals.com/info?ID=K01.172.209
Aurora Fine Chemicals LLC	K02.127.796	http://online.aurorafinechemicals.com/info?ID=K02.127.796
BioCrick	BCC4709	http://www.biocrick.com/Quinacrine-2HCl-BCC4709.html
BLD Pharm	BD149994	http://www.bldpharm.com/products/69-05-6.html
BOC Sciences	130-42-7	https://www.bocsci.com/n4-6-chloro-2-methoxyacridin-9-yl-n1-n1-diethylpentane-1-4-diamine-cas-130-42-7-item-83462.html
BOC Sciences	6151-30-0	https://www.bocsci.com/mepacrine-hcl-cas-6151-30-0-item-73187.html
Chem Scene	CS-0027605	http://www.chemscene.com/6151-30-0.html
Chem Scene	CS-4590	http://www.chemscene.com/69-05-6.html
Chemenu	CM110305	http://www.chemenu.com/products/CM110305
ChemMol	30115906	http://www.chemmol.com/chemmol/30115906.html
ChemShuttle	151922	http://www.chemshuttle.com/catalogsearch/result/?q=69-05-6&cat=
Chemspace	CSSB00020573737	https://chem-space.com/CSSB00020573737
Chemspace	CSSB00020643237	https://chem-space.com/CSSB00020643237
CSNpharm	CSN11815	https://www.csnpharm.com/products/quinacrine-dihydrochloride.html
DC Chemicals	DC22483	http://www.dcchemicals.com/product_show-DC22483.html
Debye Scientific	DB-055218	http://www.debyesci.com/cas_69-05-6.html
Enamine	Z31251611	https://www.enaminestore.com/catalog/Z31251611
eNovation Chemicals	D131877	https://www.enovationchem.com/ProductDetails.asp?ProductID=D131877
eNovation Chemicals	D388881	https://www.enovationchem.com/ProductDetails.asp?ProductID=D388881
eNovation Chemicals	D672996	https://www.enovationchem.com/ProductDetails.asp?ProductID=D672996
Finetech	FT-0631298	http://www.finetechnology-ind.com/prod/detail/pub/69-05-6.html
Finetech	FT-0674264	http://www.finetechnology-ind.com/prod/detail/pub/1189976-99-5.html
Finetech	FT-0698684	http://www.finetechnology-ind.com/prod/detail/pub/6151-30-0.html
Finetech	FT-0778222	https://www.finetechnology-ind.com/prod/detail/pub/83-89-6.html
Hairui	HR141775	http://www.hairuichem.com/en/product/6151-30-0.html
Lab Network	LN00194413	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00194413
Lab Network	LN00438137	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00438137
LGC Standards	LGCFOR1695.00	https://www.lgcstandards.com/US/en/p/LGCFOR1695.00
LGC Standards	MM1695.00	https://www.lgcstandards.com/US/en/p/MM1695.00
mcule	MCULE-3049117865	https://mcule.com/MCULE-3049117865/
mcule	MCULE-9567672915	https://mcule.com/MCULE-9567672915/
MedChem Express	HY-13735A	https://www.medchemexpress.com/Quinacrine-dihydrochloride.html
MedChem Express	HY-13735B	https://www.medchemexpress.com/quinacrine-hydrochloride-hydrate.html
Molcore	MC563510	https://www.molcore.com/product/6151-30-0
Molcore	MC567398	https://www.molcore.com/product/69-05-6
Molcore	MC573483	https://www.molcore.com/product/83-89-6
MolMall	20785	http://www.molmall.net/product/20785
MolPort	MolPort-001-739-072	https://www.molport.com/shop/molecule-link/MolPort-001-739-072
MolPort	MolPort-003-665-492	https://www.molport.com/shop/molecule-link/MolPort-003-665-492
MolPort	MolPort-018-655-037	https://www.molport.com/shop/molecule-link/MolPort-018-655-037
MuseChem	A000170	https://www.musechem.com/product/A000170.html
MuseChem	M010474	https://www.musechem.com/product/M010474.html
MuseChem	M067091	https://www.musechem.com/product/M067091.html
Selleck Chemicals	S4255	http://www.selleckchem.com/products/quinacrine-2hcl.html
Selleck Chemicals	S5435	http://www.selleckchem.com/products/quinacrine-dihydrochloride-dihydrate.html
Sigma-Aldrich	CDS020709_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/cds020709?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	PH001921_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/ph001921
Sigma-Aldrich	Q3251_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/q3251?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S011909	http://www.sinfoobiotech.com/product/1015307
Smolecule	S534971	http://www.smolecule.com/products/s534971
Smolecule	S548903	http://www.smolecule.com/products/s548903
TCI (Tokyo Chemical Industry)	Q0056	http://www.tcichemicals.com/eshop/en/us/commodity/Q0056/index.html
THE BioTek	bt-274751	https://www.thebiotek.com/product/inhibitors/bt-274751
THE BioTek	bt-288308	https://www.thebiotek.com/product/inhibitors/bt-288308
Vitas-M Laboratory	BBL028456	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL028456&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
Vitas-M Laboratory	STL061087	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=STL061087&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink

PubMed

Title	Date	PubMed
Inhibition of rat hepatic CYP2E1 by quinacrine: molecular modeling investigation and effects on 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced mutagenicity.	2009-06	18754103
Binge ethanol-induced neurodegeneration in rat organotypic brain slice cultures: effects of PLA2 inhibitor mepacrine and docosahexaenoic acid (DHA).	2009-02	18592376
ATP-induced apoptosis involves a Ca2+-independent phospholipase A2 and 5-lipoxygenase in macrophages.	2009-01	18984060
Post partum haemorrhage secondary to uterine atony, complicated by platelet storage pool disease and partial placenta diffusa: a case report.	2008-12-13	19077291
Bradykinin stimulates glutamate uptake via both B1R and B2R activation in a human retinal pigment epithelial cells.	2008-12-05	18948121
Mepacrine antagonises tumour cell growth induced by natural polyamines.	2008-11-28	19035307
Diaryl sulfide-based inhibitors of trypanothione reductase: inhibition potency, revised binding mode and antiprotozoal activities.	2008-11-07	18931800
The three-dimensional hydrogen-bonded framework structure in the 1:1 proton-transfer compound of the drug quinacrine with 5-sulfosalicylic acid.	2008-08	18682649
Mepacrine alleviates airway hyperresponsiveness and airway inflammation in a mouse model of asthma.	2008-06	18442795
Plasmodium vivax trophozoites insensitive to chloroquine.	2008-05-27	18505560
Overexpression of phospholipase D suppresses taxotere-induced cell death in stomach cancer cells.	2008-05	18190795
Comparison of nitric oxide synthase inhibitors, phospholipase A2 inhibitor and free radical scavengers as attenuators of opioid withdrawal syndrome.	2007-12	17989510
Roles of brain phosphatidylinositol-specific phospholipase C and diacylglycerol lipase in centrally administered histamine-induced adrenomedullary outflow in rats.	2007-10-01	17628524
Role of phospholipase D2 in anti-apoptotic signaling through increased expressions of Bcl-2 and Bcl-xL.	2007-08-15	17541981
Effects of age-dependent membrane transport changes on the homeostasis of senescent human red blood cells.	2007-08-15	17456724
Involvement of free radicals followed by the activation of phospholipase A2 in the mechanism that underlies the combined effects of methamphetamine and morphine on subacute toxicity or lethality in mice: comparison of the therapeutic potential of fullerene, mepacrine, and cooling.	2007-07-17	17553606
Drug, dosage, activity, studies of antimalarials by physical methods--II.	2007-05-20	18084644
Platelet adhesion onto immobilized fibrinogen under arterial and venous in-vitro flow conditions does not significantly differ between men and women.	2007-04-26	17462088
HPA-1 polymorphism of alphaIIbbeta3 modulates platelet adhesion onto immobilized fibrinogen in an in-vitro flow system.	2007-02-19	17309793
Phospholipase D1 as a key enzyme for decidualization in human endometrial stromal cells.	2007-02	17065600
Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-kappaB.	2007-01	16985215
The effects by neuroleptics, antimycotics and antibiotics on disulfide reducing enzymes from the human pathogens Acanthamoeba polyphaga and Naegleria fowleri.	2007-01	16806188
Hydrogen peroxide increases [3H]-2-deoxyglucose uptake via MAPKs, cPLA2, and NF-kappaB signaling pathways in mouse embryonic stem cells.	2007	17975303
Oral given Mepacrine could increase the resistance to heat environment injury.	2007	17023118
Roles of P2 receptors in glial cells: focus on astrocytes.	2006-11	18404462
Hypoxia-induced sickness behaviour.	2006-11	17242471
Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children.	2006-10-21	17072963
Antithrombin significantly influences platelet adhesion onto immobilized fibrinogen in an in-vitro system simulating low flow.	2006-10-13	17040572
Activity of picolinic acid in combination with the antiprotozoal drug quinacrine against Mycobacterium avium complex.	2006-09	16940126
In vitro antiproliferative effects of neuroleptics, antimycotics and antibiotics on the human pathogens Acanthamoeba polyphaga and Naegleria fowleri.	2006-08	16824931
Mechanism of induction of muscle protein degradation by angiotensin II.	2006-07	16257180
Arachidonic acid induces ERK activation via Src SH2 domain association with the epidermal growth factor receptor.	2006-05	16598196
The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.	2006-04	16623930
A novel role of phospholipase A2 in mediating spinal cord secondary injury.	2006-04	16498630
Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances.	2006	16396521
Blood schizontocidal activity of azithromycin and its combination with alpha/beta arteether against multi-drug resistant Plasmodium yoelii nigeriensis, a novel MDR parasite model for antimalarial screening.	2005-09	16178350
High cystine in platelets from patients with nephropathic cystinosis: a chemical, ultrastructural, and functional evaluation.	2005-09	16126874
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.	2005-09	15923343
Acridine derivatives activate p53 and induce tumor cell death through Bax.	2005-08	16177561
Role of contractile prostaglandins and Rho-kinase in growth factor-induced airway smooth muscle contraction.	2005-07-27	16048647
Re: Martin TJM, Sharp I, Oral mucosal pigmentation secondary to treatment with mepacrine, with sparing of the denture bearing area (Br J Oral Maxillofac Surg 2004;42:351-3).	2005-06	15888372
Brain phospholipase C/diacylglycerol lipase are involved in bombesin BB2 receptor-mediated activation of sympatho-adrenomedullary outflow in rats.	2005-05-09	15910801
Serum ferritin elevation and acute lung injury in rats subjected to hemorrhage: reduction by mepacrine treatment.	2004-09-17	15371093
Scar sarcoidosis following tattooing of the lips treated with mepacrine.	2004-09	15347351
Involvement of protein kinase C activation in L-leucine-induced stimulation of protein synthesis in l6 myotubes.	2003-11	19003213
Possible involvement of phospholipase C and protein kinase C in stimulatory actions of L-leucine and its keto acid, alpha-ketoisocaproic acid, on protein synthesis in RLC-16 hepatocytes.	2002-11	19003115
Camp laparoscopic sterilization deaths in Gujarat State, India, 1978-1980.	1991-12	1839351
Anti-cryptosporidial drug activity screened with an immunosuppressed rat model.	1991-11-01	1818183
A Comparative Study of Hymenolepicides in Hymenolepis Mana Infestation of Rats.	1962-07	17649381
RETINOPATHY DURING CHLOROQUINE THERAPY.	1961-11	18170732

Patents

Sample Use Guides

In Vivo Use Guide

Capsule: 25‐200 mg, Suppositories: 25-100 mg.

Route of Administration: Other

In Vitro Use Guide

The concentration of Quinacrine needed to reduce Candida albicans biofilm metabolic activity by 50% (sMIC50) was 256 ug/ml, and the concentration needed to reduce Candida albicans biofilm metabolic activity by 90% (sMIC90) was 1,024 ug/ml.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:46:21 GMT 2025` Edited by `admin` on `Mon Mar 31 17:46:21 GMT 2025`
Record UNII	H0C805XYDE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MEPACRINE

Preferred Name

English

QUINACRINE

Common Name

English

Mepacrine [WHO-DD]

Common Name

English

QUINACRINE [VANDF]

Common Name

English

QUINACRINE [HSDB]

Common Name

English

ATABRINE

Brand Name

English

mepacrine [INN]

Common Name

English

QUINACRINE [MI]

Common Name

English

6-CHLORO-9-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)-2-METHOXYACRIDINE

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

379912